Medline Inc. posted a 10.4% increase in net sales to $7.9 billion for Q3 2026, driven by new and existing customer growth. However, net income slightly declined by 1.2% to $318 million due to higher inventory costs and operating expenses. Adjusted EBITDA rose 11.8% to $960 million. The company raised its full-year 2026 organic sales growth guidance to 10.0%-10.5% and authorized a $1 billion share repurchase program, signaling confidence in its growth prospects despite some cost pressures.
Medline Inc.'s stock surged 10.00% to USD 37.50 on Pluang as of Nov 04, 2026 19:42 WIB, reflecting strong investor interest following the company's robust Q3 sales growth and share repurchase announcement. The stock trades with a market cap of $29.91 billion and a 52-week range between $31.64 and $49.99. Pluang users show high confidence with 98% buy orders and a typical hold time of 9 days.
Medline Inc. is under investigation for potential securities fraud after the FDA issued a warning about significant manufacturing violations. The company's stock fell 7% in June and 13% in August following disclosures of quality issues and earnings l...
Medline Inc. announced that CEO Jim Boyle will present at the Jefferies Global Healthcare Conference in London on November 17, 2026. The presentation will be webcast live and available for replay on Medline's Investor Relations website. This event hi...
